Individualized ocular characteristics should be considered before starting GLP-1 RA therapies for weight loss and diabetes management.

USA: Researchers have found in a new study that patients with idiopathic intracranial hypertension (IIH) treated with ...

Longer treatment duration, using semaglutide, higher percentage body fat, and nondiabetic status may be associated with better weight reduction.

GLP-1 receptor agonists such as semaglutide and liraglutide promote significant weight loss and improved glycemic control, ...

Researchers have determined in a new study that the glucagon-like peptide-1 receptor agonists (GLP-1 RAs) lower the risk of ...

Glucagon-like peptide 1 receptor agonist (GLP-1 RA) therapy in idiopathic intracranial hypertension is associated with significant reductions in medication use, symptoms/signs, and procedural ...

A Trump administration proposal to consider another form of drugs for Medicare price cuts is spurring legal and policy ...

A population-based cohort study emulating a target trial estimated the effect of glucagon-like peptide-1 receptor agonists ...

SGLT2 inhibitors, compared with GLP-1 RAs, were associated with lower risks for osteoarthritis and joint replacement surgery among patients with T2D.

GLP-1 RAs are associated with a modestly increased risk for GERD and gallstone disease but not with GI and biliary complications.

Historically, managing type 2 diabetes in advanced chronic kidney disease (CKD) has been challenging due to a lack of therapies and increased risks for adverse events.

A US doctor has explained the reality behind the 'Ozempic penis' side effect men have reported having after taking the GLP-1 drug ...